Expression and regulation of IFNα/β receptor in IFNβ-treated patients with multiple sclerosis

被引:34
作者
Gilli, F. [1 ]
Valentino, P.
Caldano, M.
Granieri, L.
Capobianco, M.
Malucchi, S.
Sala, A.
Marnetto, F.
Bertolotto, A.
机构
[1] ASO S Luigi Gonzaga, Ctr Riferimento Reg Sclerosi Multipla CRESM, I-10043 Turin, Italy
关键词
D O I
10.1212/01.wnl.0000327340.50284.8d
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The cytokine interferon beta (IFN beta) is successfully used in the treatment of multiple sclerosis (MS), although there is a high degree of variability in the response. A common mechanism involved in the modulation of responsiveness to cytokines is represented by regulation of their receptor expression through autocrine ligand-mediated loops. The present study is aimed at investigating the regulation of IFN alpha/beta receptor (IFNAR) during IFN beta therapy in patients with MS and at correlating it with the biologic responsiveness to the cytokine. Methods: Quantitative PCR measurements of IFNAR-1 and the three IFNAR-2 isoforms were performed in 141 patients after short-term and long-term treatment. Patients were also regularly screened for anti-IFN beta neutralizing antibodies (NAbs). IFN-inducible myxovirus resistance protein A messenger RNA was used as an indicator of bioactivity. Results: Pretreatment levels of IFNAR-2 in patients were lower overall than in controls (p = 0.038), and high levels correlated with greater bioactivity. Upon prolonged treatment, NAb-negative patients displayed a state of decreased transmembrane IFNAR-2 expression (p <= 0.025), whereas levels of soluble IFNAR-2 were slightly increased (p < 0.0001). The presence of NAbs reversed these effects (p <= 0.0056). In NAb-positive patients, pretreatment expression levels of both transmembrane IFNAR-2 isoforms were significantly lower than in NAb-negative patients (p <= 0.0089). Conclusions: Findings show that interferon-alpha/beta receptor (IFNAR)-2 isoforms are important regulators of the responsiveness to endogenous and systemically administered interferon beta (IFN beta). They show a dual action, agonistic and antagonistic, that influences both the magnitude and the nature of the biologic response to IFN beta. Levels of IFNAR-2 are regulated with the aim of keeping the body in a state of equilibrium, even when nonphysiologic stimuli are present.
引用
收藏
页码:1940 / 1947
页数:8
相关论文
共 37 条
[1]   Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients [J].
Bertolotto, A ;
Gilli, F ;
Sala, A ;
Capobianco, M ;
Malucchi, S ;
Milano, E ;
Melis, F ;
Marnetto, F ;
Lindberg, RLP ;
Bottero, R ;
Di Sapio, A ;
Giordana, MT .
NEUROLOGY, 2003, 60 (04) :634-639
[2]   CORRELATION BETWEEN THE BIOLOGICAL AND THERAPEUTIC EFFECTS OF INTERFERON-ALPHA IN LOW-GRADE NODULAR NON-HODGKINS-LYMPHOMA - LACK OF INVIVO DOWN-REGULATION AND REDUCED AFFINITY OF IFN-ALPHA RECEPTORS IN UNRESPONSIVE PATIENTS [J].
BILLARD, C ;
FERBUS, D ;
DIEZ, RA ;
KOLB, JP ;
MATHIOT, C ;
BELANGER, C ;
AUZANNEAU, G ;
VARET, B ;
FALCOFF, E ;
DUMONT, J .
LEUKEMIA RESEARCH, 1991, 15 (2-3) :121-128
[3]   ENHANCED INTERFERON-ALPHA-BETA(IFN-ALPHA-BETA) AND DEFECTIVE IFN-GAMMA PRODUCTION IN CHRONIC GRAFT VERSUS HOST-DISEASE - A POTENTIAL MECHANISM FOR IMMUNOSUPPRESSION [J].
CLEVELAND, MG ;
LANE, RG ;
KLIMPEL, GR .
CELLULAR IMMUNOLOGY, 1987, 110 (01) :120-130
[4]   DIRECT BINDING TO AND TYROSINE PHOSPHORYLATION OF THE ALPHA-SUBUNIT OF THE TYPE-I INTERFERON RECEPTOR BY P135(TYK2) TYROSINE KINASE [J].
COLAMONICI, O ;
YAN, H ;
DOMANSKI, P ;
HANDA, R ;
SMALLEY, D ;
MULLERSMAN, J ;
WITTE, M ;
KRISHNAN, K ;
KROLEWSKI, J .
MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (12) :8133-8142
[5]   Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies [J].
Deisenhammer, F ;
Reindl, M ;
Harvey, J ;
Gasse, T ;
Dilitz, E ;
Berger, T .
NEUROLOGY, 1999, 52 (06) :1239-1243
[6]   Mechanisms for regulation of cellular responsiveness to human IFN-β1a [J].
Dupont, SA ;
Goelz, S ;
Goyal, J ;
Green, M .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2002, 22 (04) :491-501
[7]   Post-translational up-regulation of the cell surface-associated alpha component of the human type I interferon receptor during differentiation of peripheral blood monocytes: Role in the biological response to type I interferon [J].
Fantuzzi, L ;
Eid, P ;
Malorni, W ;
Rainaldi, G ;
Gauzzi, MC ;
Pellegrini, S ;
Belardelli, F ;
Gessani, S .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (05) :1075-1081
[8]   Results following development of neutralizing antibodies in PRISMS [J].
Francis, GS ;
Rice, GPA ;
Alsop, JC .
NEUROLOGY, 2005, 65 (01) :48-55
[9]   Loss of type IIFN receptors and impaired IFN responsiveness during terminal maturation of monocyte-derived human dendritic cells [J].
Gauzzi, MC ;
Canini, I ;
Eid, P ;
Belardelli, F ;
Gessani, S .
JOURNAL OF IMMUNOLOGY, 2002, 169 (06) :3038-3045
[10]   Neutralizing antibodies against IFN-β in multiple sclerosis:: antagonization of IFN-β mediated suppression of MMPs [J].
Gilli, F ;
Bertolotto, A ;
Sala, A ;
Hoffmann, F ;
Capobianco, M ;
Malucchi, S ;
Glass, T ;
Kappos, L ;
Lindberg, RLP ;
Leppert, D .
BRAIN, 2004, 127 :259-268